Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data ; volume:26 ; number:4 ; day:17 ; month:4 ; year:2024 ; pages:441-450 ; date:7.2024
Pediatric drugs ; 26, Heft 4 (17.4.2024), 441-450, 7.2024
- Urheber
-
Nassar-Sheikh Rashid, Amara
Hooijberg, Femke
Bergkamp, Sandy C.
Gruppen, Mariken P.
Kuijpers, Taco W.
Nurmohamed, Mike
Rispens, Theo
Wolbink, Gertjan
Berg, J. Merlijn van den
Schonenberg-Meinema, Dieneke
Mathôt, Ron A. A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40272-024-00629-7
- URN
-
urn:nbn:de:101:1-2409122103416.861409685852
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nassar-Sheikh Rashid, Amara
- Hooijberg, Femke
- Bergkamp, Sandy C.
- Gruppen, Mariken P.
- Kuijpers, Taco W.
- Nurmohamed, Mike
- Rispens, Theo
- Wolbink, Gertjan
- Berg, J. Merlijn van den
- Schonenberg-Meinema, Dieneke
- Mathôt, Ron A. A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Juvenile idiopathic arthritis-associated uveitis
Haptoglobin in Juvenile Idiopathic Arthritis
Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Juvenile idiopathic arthritis-associated uveitis
Haptoglobin in Juvenile Idiopathic Arthritis
Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Juvenile idiopathic arthritis-associated uveitis